NCT00871117View on ClinicalTrials.gov

Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years

PHASE3CompletedINTERVENTIONAL
Enrollment

478

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

January 15, 2010

Study Completion Date

June 15, 2010

Conditions
TetanusAcellular PertussisDiphtheria
Interventions
BIOLOGICAL

GSK Biologicals'Kinrix®

One dose as intramuscular injection at visit 1

BIOLOGICAL

Merck and Company's MMRII

One dose as subcutaneous injection at visit 1

BIOLOGICAL

Merck and Company's Varivax

One dose as subcutaneous injection at visit 1 or at visit 2

Trial Locations (11)

94015

GSK Investigational Site, Daly City

94063

GSK Investigational Site, Redwood City

94509

GSK Investigational Site, Antioch

94545

GSK Investigational Site, Hayward

94589

GSK Investigational Site, Vallejo

94596

GSK Investigational Site, Walnut Creek

95119

GSK Investigational Site, San Jose

95403

GSK Investigational Site, Santa Rosa

95661

GSK Investigational Site, Roseville

95815

GSK Investigational Site, Sacramento

95823

GSK Investigational Site, Sacramento

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00871117 - Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years | Biotech Hunter | Biotech Hunter